Abstract
Cardiovascular disease is the leading cause of morbidity and mortality worldwide. Long-term use of antiplatelet drugs is a well-studied therapy for the prevention of cardiovascular death. Ensuring compliance with lifelong administration of antiplatelet drugs, in particular acetylsalicylic acid, is one of the challenges of such therapy. The aim of this study is to explore the possibility of using nuclear magnetic resonance spectroscopy to identify acetylsalicylic acid metabolites in urine and to search for characteristic markers that could be used to detect patient compliance with long-term acetylsalicylic acid treatment.
Highlights
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality among individuals worldwide
In this work we focused our attention on the study of acetylsalicylic acid (ASA) metabolites in urine, taking into account the fact that, in blood, salicylic acid (SA) produced after administration of aspirin has a biological half-life of 2–4 hours, so the concentration of salicylate in urine, at least in the form its major metabolite salicyluric acid (SU), is significantly higher than in serum [12, 21] and blood plasma
We found that in healthy volunteers who took therapeutic doses of 100, 300 and 3000 mg of aspirin, salicyluric acid accounts for the most intense peaks of aspirin metabolites in 1H nuclear magnetic resonance (NMR) spectra, with the most intense group of signals observed in the region between 6.6 and 6.9 ppm
Summary
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality among individuals worldwide. In 2017, CVD caused an estimated 17.8 million deaths globally, corresponding to 330 million years of life lost and another 35.6 million years lived with disability [1, 2]. Several approaches have been developed and applied in assessing adherence to aspirin: pill counting, interviewing patients, evaluating platelet function, determining aspirin metabolites in blood and urine. Few studies have measured levels of acetylsalicylic acid (ASA) metabolites in patients with CVD taking ASA for CVD prevention [4, 5]. The most rational approach for monitoring ASA ingestion is to identify two main ASA metabolites (SA and SU) in blood or in urine
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
